江蘇雷利(300660.SZ):子公司鼎智科技提交北交所上市輔導材料
格隆匯12月29日丨江蘇雷利(300660.SZ)公佈,公司的控股子公司江蘇鼎智智能控制科技股份有限公司(簡稱“鼎智科技”)為全國中小企業股份轉讓系統掛牌企業,證券簡稱:鼎智科技,證券代碼:873593。公司持有鼎智科技57.22%股份。
2021年12月28日鼎智科技與中信建投簽訂了《江蘇鼎智智能控制科技股份有限公司與中信建投證券股份有限公司關於向不特定合格投資者公開發行股票並在北京證券交易所上市項目之輔導協議》。目前,鼎智科技正在接受中信建投的輔導。
鼎智科技於2021年12月29日向江蘇證監局提交了公開發行股票並在北京證券交易所上市輔導備案材料,輔導機構為中信建投。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.